INT19158

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 1980
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 35
Total Number 37
Disease Relevance 35.81
Pain Relevance 3.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PAH) small molecule metabolic process (PAH) cellular nitrogen compound metabolic process (PAH)
Anatomy Link Frequency
plasma 2
fibroblasts 2
capillary 2
smooth muscle 1
liver 1
PAH (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 368 100.00 Very High Very High Very High
anesthesia 14 98.72 Very High Very High Very High
fluoxetine 3 97.68 Very High Very High Very High
Serotonin 14 93.32 High High
isoflurane 9 93.28 High High
drug abuse 1 91.80 High High
alcohol 6 91.20 High High
Inflammation 130 91.04 High High
opioid receptor 84 90.08 High High
Inflammatory response 34 88.96 High High
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 1794 100.00 Very High Very High Very High
Hypoxia 397 100.00 Very High Very High Very High
Pressure And Volume Under Development 191 100.00 Very High Very High Very High
Hypertension 117 100.00 Very High Very High Very High
Sarcoidosis 76 100.00 Very High Very High Very High
Pheochromocytoma 50 100.00 Very High Very High Very High
Phenylketonuria 1 100.00 Very High Very High Very High
Anaemia 15 99.96 Very High Very High Very High
Paraganglioma 48 99.92 Very High Very High Very High
Hyperplasia 27 99.80 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.
Gene_expression (clearance) of PAH in plasma
1) Confidence 0.65 Published 1991 Journal Anesthesiology Section Abstract Doc Link 2021202 Disease Relevance 0.39 Pain Relevance 0.41
PM-associated PAHs present under idling conditions were distributed as a higher number of compounds, including heavier PAH (4-rings) species (Figure 7).
Gene_expression (present) of PAH
2) Confidence 0.65 Published 2010 Journal Part Fibre Toxicol Section Body Doc Link PMC2918524 Disease Relevance 0 Pain Relevance 0
Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were determined by measuring inulin and PAH clearance respectively, along with plasma renin activity (PRA) and urinary electrolyte excretion before and over 100 minutes after drug administration.
Gene_expression (clearance) of PAH in plasma
3) Confidence 0.65 Published 2001 Journal Swiss Med Wkly Section Body Doc Link 11345810 Disease Relevance 0 Pain Relevance 0
Screening includes programs for the detection of PKU and congenital hypothyroidism in newborn infants, for spina bifida cystica in the unborn fetus, and hypertension.
Gene_expression (detection) of PKU in spina associated with spina bifida cystica, phenylketonuria, hypertension and cretinism
4) Confidence 0.60 Published 1980 Journal Med Care Section Abstract Doc Link 6772886 Disease Relevance 0.67 Pain Relevance 0.16
Eligible PAH patients diagnosed by PAH by a board certified pulmonologist (CGE) based on clinical and laboratory data, and the 2003 World Health Organization classification guidelines were evaluated for this study.
Gene_expression (diagnosed) of PAH associated with pulmonary hypertension
5) Confidence 0.59 Published 2006 Journal Respir Res Section Body Doc Link PMC1448205 Disease Relevance 2.61 Pain Relevance 0.15
According to the World Health Organization Revised Clinical Classification of Venice (Simonneau et al 2004), pulmonary arterial hypertension (PAH) is a specific subtype of PH with a pulmonary capillary wedge pressure (PCWP) ?
Gene_expression (subtype) of PH in capillary associated with pulmonary hypertension
6) Confidence 0.58 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 1.67 Pain Relevance 0.06
Therapies for PH
Gene_expression (Therapies) of PH associated with pulmonary hypertension
7) Confidence 0.58 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 1.22 Pain Relevance 0.04
In the open-label extension seven serious adverse events occurred: cardiac failure and anemia, progression of PAH, abnormal liver enzymes (n = 3), 1 death after seizures probably caused by vasculitis reactivation, and an episode of toxic epidermal necrolysis and acute hepatitis.36 Postmarketing surveillance reports have flagged hypersensitivity, rash, thrombocytopenia, jaundice, anemia requiring transfusion and hepatic cirrhosis/failure as serious adverse events.
Gene_expression (progression) of PAH in liver associated with staphylococcus infection, cirrhosis, cv general 4 under development, hypersensitivity, increased venous pressure under development, exanthema, pulmonary hypertension, anaemia, convulsion, thrombocytopenia, jaundice, death and hepatitis
8) Confidence 0.58 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 1.82 Pain Relevance 0.09
The first published trial of inhaled treprostinil in humans characterized its effects in three patients with severe PAH.74 After right heart catheterization, each patient received a single administration of 15 ?
Gene_expression (severe) of PAH in heart associated with pulmonary hypertension
9) Confidence 0.57 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC3004515 Disease Relevance 0.52 Pain Relevance 0.06
Sitaxsentan was the first ET-A specific receptor antagonist for the treatment of PAH.
Gene_expression (antagonist) of PAH associated with pulmonary hypertension and antagonist
10) Confidence 0.57 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC3004515 Disease Relevance 0.42 Pain Relevance 0.05
The sensitivity and specificity for detecting PAH is 0.79 to 1.00 and 0.68 to 0.98, respectively.
Gene_expression (detecting) of PAH associated with pulmonary hypertension
11) Confidence 0.57 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC3004515 Disease Relevance 1.16 Pain Relevance 0.07
The pathogenesis of the development of PAH is proposed to be multifactorial, involving genetic factors such as the transforming growth factor beta (TGF-?)
Gene_expression (development) of PAH associated with pulmonary hypertension
12) Confidence 0.55 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663441 Disease Relevance 1.18 Pain Relevance 0.29
In fact, PH may not be deadly in itself: young adult mice and rats survive and develop stable PH within 3 weeks of 50% hypoxia (11% FIO2 or 0.5 atm) ([21-24], plus recurrent personal observation), and it was recently shown in rats that if hypoxia (0.5 atm) is maintained death does not occur until the rats are aged [25].
Neg (not) Gene_expression (deadly) of PH associated with pulmonary hypertension, hypoxia and death
13) Confidence 0.55 Published 2006 Journal Respir Res Section Body Doc Link PMC1764736 Disease Relevance 1.72 Pain Relevance 0
Combination therapy in PAH
Gene_expression (therapy) of PAH associated with pulmonary hypertension
14) Confidence 0.50 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.98 Pain Relevance 0
Patients with chronic thrombo-embolic disease not amenable to surgery can be considered for treatment with specific PAH therapies.15 Detailed discussion of the differences between various subgroups and the formulation of treatment algorithms is beyond the scope of this review, and further information can be found in other articles.1,6,16
Gene_expression (discussion) of PAH associated with pulmonary hypertension, embolism and disease
15) Confidence 0.50 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 1.52 Pain Relevance 0.12
Endothelin receptor subtype A (ETA) is predominantly found in smooth muscle and also on fibroblasts, whereas receptor subtype B (ETB) is expressed on smooth muscle and endothelial cells.19 Endothelial ETB activation mediates clearance of endothelin-1 and vasodilatation by nitric oxide and prostacyclin release.18 Because of these effects ETB activation is theoretically desirable in PAH.
Gene_expression (desirable) of PAH in fibroblasts associated with pulmonary hypertension and increased venous pressure under development
16) Confidence 0.50 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.56 Pain Relevance 0.14
Chronic hypoxia provoked PH in old mice
Gene_expression (provoked) of PH associated with pulmonary hypertension and hypoxia
17) Confidence 0.48 Published 2006 Journal Respir Res Section Body Doc Link PMC1764736 Disease Relevance 1.58 Pain Relevance 0.04
Hypoxic death in old animals: a model for PH survival?
Gene_expression (survival) of PH associated with pulmonary hypertension, hypoxia and death
18) Confidence 0.48 Published 2006 Journal Respir Res Section Body Doc Link PMC1764736 Disease Relevance 1.71 Pain Relevance 0.04
DHEA prevented hypoxic PH in mice
Gene_expression (hypoxic) of PH associated with pulmonary hypertension and hypoxia
19) Confidence 0.48 Published 2006 Journal Respir Res Section Body Doc Link PMC1764736 Disease Relevance 1.62 Pain Relevance 0.04
It has previously been shown that PAHs in the diesel fuel represent a significant source for exhaust PAHs, besides the pyrosynthesis of exhaust PAH [33,34].
Gene_expression (pyrosynthesis) of PAH
20) Confidence 0.39 Published 2010 Journal Part Fibre Toxicol Section Body Doc Link PMC2918524 Disease Relevance 0.22 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox